James Marino Biography and Net Worth

Director of Onconova Therapeutics

Mr. Marino brings more than three decades of experience advising numerous leading life science companies in connection with corporate transactions and strategic alliances. He has served as a Director of Onconova since July 2015, a Director of Celldex Therapeutics, Inc. since March 2017, and previously as a Director of Pharmacopeia, Inc. Mr. Marino served on the Board of Trustees of Wake Forest University and its renowned Medical Center, and previously served on the Board of Trustees of Robert Wood Johnson University Hospital. He is a co-founder of BioNJ, a trade association of biotechnology companies. Mr. Marino was a partner with the global law firm of Dechert LLP for 28 years, where he served as Managing Partner of the Princeton, N.J. office, and focused on the representation of leading life sciences companies in a broad range of corporate transactions including innovative strategic alliances, joint-ventures, and spin-offs. Mr. Marino received his B.A., J.D., and MBA from Rutgers University.

What is James J. Marino's net worth?: The estimated net worth of James J. Marino is at least $0.00 as of February 16th, 2021. Mr. Marino owns 230,716 shares of Onconova Therapeutics stock worth more than $0 as of December 2nd. This net worth evaluation does not reflect any other assets that Mr. Marino may own. Learn More about James J. Marino's net worth.
How do I contact James J. Marino?: The corporate mailing address for Mr. Marino and other Onconova Therapeutics executives is 375 PHEASANT RUN, NEWTOWN PA, 18940. Onconova Therapeutics can also be reached via phone at (267) 759-3680 and via email at [email protected]. Learn More on James J. Marino's contact information.
Has James J. Marino been buying or selling shares of Onconova Therapeutics?: James J. Marino has not been actively trading shares of Onconova Therapeutics in the last ninety days. Most recently, on Tuesday, September 28th, James J. Marino bought 5,952 shares of Onconova Therapeutics stock. The stock was acquired at an average cost of $4.20 per share, with a total value of $24,998.40. Learn More on James J. Marino's trading history.
Who are Onconova Therapeutics' active insiders?: Onconova Therapeutics' insider roster includes Steven Fruchtman (Insider), James Marino (Director), and Abraham Oler (SVP). Learn More on Onconova Therapeutics' active insiders.

James J. Marino Insider Trading History at Onconova Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/28/2021	Buy	5,952	$4.20	$24,998.40
2/16/2021	Buy	25,000	$1.00	$25,000.00	230,716
11/24/2020	Buy	38,774	$0.26	$10,081.24	205,716
9/25/2019	Buy	7,260	$1.60	$11,616.00	16,942

James J. Marino Buying and Selling Activity at Onconova Therapeutics

Onconova Therapeutics Company Overview

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Today's Range

Now: N/A

50 Day Range

MA: $0.85

$0.67

$1.01

2 Week Range

Now: N/A

Volume

1,281,800 shs

Average Volume

96,681 shs

Market Capitalization

$20.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

Musk’s new company could top a trillion?

From Paradigm Press | Ad

The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.

Click here to see the details because there’s not much time to prepare.